To assess the dual-targeting approach on FLT3-ITD leukemic cells, the cytotoxicity of the Co-Assembled nanoparticles was tested in a panel of AML cell lines, MV4-11 and MOLM-13 cells which both possess the FLT3-ITD mutation and overexpression of CD99, U937 cells which are absent of FLT3 but express CD99, and THP-1 cells which express the FLT3-WT and CD99. The gene discussed is FLT3; the disease is acute myeloid leukemia.